MedTrace Logo

Feasibility Study of New Method of Diagnostic and Prediction of Painful CIPN

NCT03206216 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2018-12-19

Study results available
· View outcomes & findings →

Summary

This clinical trial studies how well Diode laser fiber type Selective Stimulator (DLss) works in predicting pain development in patients with ovarian cancer who are receiving chemotherapy. Stimulating of the pain nerve fibers in the skin with laser light stimulation may help to predict whether a patient will develop painful peripheral neuropathy, correlate with the severity of neuropathy during and after chemotherapy treatment, and may help to explain the mechanisms of chemotherapy-induced neuropathic pain (CIPN).

Conditions

  • Burning Pain
  • Impaired Balance
  • Malignant Ovarian Neoplasm
  • Numbness
  • Peripheral Neuropathy
  • Pain, Acute
  • Tingling

Interventions

DIAGNOSTIC_TEST

Diode Laser fiber type Selective Stimulator (DLss)

A laser device to assess pain sensitivity to stimulation

Sponsors & Collaborators

Principal Investigators

  • Oliver Dorigo, MD, PhD · Stanford University

  • Seema Nagpal, MD · Stanford University

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-04
Primary Completion
2017-10-30
Completion
2017-10-30
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03206216 on ClinicalTrials.gov